Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.59 |
| ▸ | AHCY | P23526 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259774 | 0.93 | ADORA3 (0.59) | ADORA3ADORA1ADORA2AADORA2BAHCY | |
| SCHEMBL6260702 | 0.90 | AHCY (0.56) | ADORA3ADORA1ADORA2AADORA2BAHCY | |
| SCHEMBL6258386 | 0.90 | AHCY (0.56) | ADORA3ADORA1ADORA2AADORA2BAHCY | |
| SCHEMBL6259472 | 0.89 | ADORA3 (0.73) | ADORA3ADORA1ADORA2AADORA2BAHCY | |
| SCHEMBL6257340 | 0.88 | AHCY (0.60) | ADORA3ADORA1ADORA2AAHCY | |
| SCHEMBL6261537 | 0.85 | AHCY (0.57) | ADORA3ADORA1ADORA2AADORA2BAHCY | |
| SCHEMBL6260861 | 0.85 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BAHCY | |
| SCHEMBL6263669 | 0.84 | PRKAB2 (0.49) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6263661 | 0.84 | PRKAB2 (0.49) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6263664 | 0.84 | PRKAB2 (0.49) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | claimed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | claimed |
| EP-1370568-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | claimed |
| WO-2002074780-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | claimed |
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | disclosed |
| EP-1370568-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074780-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | ADORA1, ADORA2A, ADORA2B | ADORA3 4/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.